• PDF / 169,605 Bytes
• 1 Pages / 595.245 x 841.846 pts (A4) Page_size
• 13 Downloads / 176 Views

DOWNLOAD

REPORT

---

1

S

Pancytopenia: case report A 65-year-old woman developed pancytopenia following radionuclide treatment with lutetium-177-DOTA-zoledronate and following chemotherapy with cyclophosphamide and doxorubicin [routes and dosages not stated]. The woman had breast cancer with multiple bone-only metastases in the axial and appendicular parts of the skeleton. She received 3700 MBq of lutetium-177-DOTA-zoledronate [177-DOTA Zoledronic acid] as bone pain palliation therapy. Additionally, she received 2 cycles of doxorubicin [adriamycin] and cyclophosphamide [Cytoxan]. However, she developed pancytopenia 5 days after the therapy that lasted nearly 7 weeks. Her bone lesions were found to be decreased after the therapy. Author comment: "The main adverse effect was pancytopenia detected after 5 days, lasted nearly 7 weeks, which was difficult to differentiate whether this was due to the radionuclide treatment or concurrent/ongoing chemotherapy." Novruzov F, et al. First clinical experience using 177Lu-zoledronate for the treatment of skeletal metastases in breast Cancer: 68Ga- NODAGA-ZOL PET-CT imaging for patients eligibility and follow-up. European Journal of Nuclear Medicine and Molecular Imaging 46 (Suppl. 1): S239-S240 (plus oral presentation) abstr. OP-625, No. 1, Oct 2019. Available from: URL: http://doi.org/10.1007/ 803433828 s00259-019-04486-2 [abstract] - Azerbaijan

0114-9954/19/1779-0001/$14.95 Adis © 2019 Springer Nature Switzerland AG. All rights reserved

Reactions 16 Nov 2019 No. 1779